Communication of teratogenicity risk with dolutegravir
- PDF / 169,976 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 27 Downloads / 197 Views
1
Communication of teratogenicity risk with dolutegravir The process used by a Ugandan clinic to communicate the risk of teratogenicity to pregnant women receiving dolutegravir "can act as a model for response", according to study results reported in Drug Safety. Within the week following a safety alert for dolutegravir (DTG) related to a risk of neural tube defects in May 2018, a response plan was developed by the Infectious Diseases Institute adult clinic in Kampala. All 690 female dolutegravir recipients
Data Loading...
